Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Fenretinide (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors CerRx
- 08 Feb 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
- 08 Feb 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
- 08 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.